Cabaletta Bio

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Cabaletta Bio, Inc. (CABA) Is a Great Choice for 'Trend' Investors, Here's Why

Cabaletta Bio rallied hard in late FY22 with shares running up the page in near-linear fashion. The rally has extended to today's mark and we are looking to add to our position with another ticket of 500 shares.

Cabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)

PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Thursday, January 12th at 7:30 a.m. PT (10:30 a.m. ET).

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

AVEO Pharma

Verona Pharma

Wave Life Sciences

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

4 Drug Stocks That More Than Doubled This Year

The mean of analysts' price targets for Cabaletta Bio, Inc. (CABA) points to a 60% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Cabaletta Bio, Inc. (CABA) Climb 60% to Reach the Level Wall Street Analysts Expect?

PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022 at 9:40 a.m. ET.

Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference

EyePoint Pharmaceuticals

Milestone Pharmaceuticals Inc

Superior Industries International

Tenaya Therapeutic

Analysts say these are penny stocks to buy. Do you agree?

5 Penny Stocks To Buy According To Analysts, Targets Up To 992%

PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.

Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

CNB Financial Corp.

Enviva Partners

Merchants Bancorp

Dave & Buster's

According to the Insider Cluster Buys screen, a Premium feature of GuruFocus, five stocks that had a high number of company insiders buying shares over the past month were CNB Financial Corp. ( CCNE , Financial), Enviva Inc. ( EVA , Financial), Merchants Bancorp ( MBIN , Financial), Cabaletta Bio Inc. ( CABA , Financial) and Dave & Buster's Entertainment Inc. ( PLAY , Financial).

5 Stocks Insiders Are Buying in October

IMARA

Ngm Biopharmaceuticals Inc

Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Best Penny Stocks To Buy Before November According To Insiders

Applied Therapeutics Inc

Doma Holdings

Canoo

Mind Medicine MindMed

Nine Energy Service

Oblong

Quoin Pharmaceuticals Ltd

Founder SPAC

Viking Therapeutics

Penny stocks to buy according to analysts in 2022. The post 10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022

PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational data from the DesCAARTes™ trial of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) in a poster presentation at the upcoming 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), which is being held at the Edinburgh International Conference Centre in Edinburgh, Scotland from October 11-14, 2022.

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A4 as well as 28-day safety data and DSG3-CAART persistence data through day 29 for cohorts A1 through A5 from the DesCAARTes™ trial at the 31st European Academy of Dermatology and Venereology (EADV) Congress, which is being held in Milan, Italy from September 7-10, 2022.

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

PHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present new clinical and translational data from cohort A4 and safety data from cohort A5 in the DesCAARTes™ trial of DSG3-CAART in a late-breaking oral presentation at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress, which is being held virtually and in person in Milan, Italy from September 7-10, 2022.

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a business update.

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock

Cabaletta Bio Inc (NASDAQ: CABA) presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV), a blistering skin disease that affects mucous membranes. No dose-limiting toxicities were observed within three months.

Cabaletta Bio's Updated Interim DSG3-CAART Data Fails To Cheer Investors

PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A3, safety data through 3 months and persistence data through 1 month of follow-up in cohorts A1 through A4 from the DesCAARTes™ trial at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held in Washington, D.C. from May 16-19, 2022.

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 –

Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that data from its two lead programs, DSG3-CAART and MuSK-CAART, will be presented at multiple upcoming scientific meetings in May 2022. The DSG3-CAART presentations will include Phase 1 clinical data from the ongoing DesCAARTes™ trial. The MuSK-CAART presentations will contain preclinical safety and activity studies to support potential clinical development of precision engineered T-cell therapy for MuSK-associated myasthenia gravis.

Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May

New York, New York--(Newsfile Corp. - April 29, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) . This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about...

CABA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cabaletta Bio, Inc

New York, New York--(Newsfile Corp. - April 29, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or...

CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - April 29, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta" or "the Company") (NASDAQ: CABA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the prospectus which incorporated and formed part of the registration statement (the "Prospectus" and, together with the Registration...

Bronstein, Gewirtz & Grossman, LLC Reminds Cabaletta Bio, Inc. (CABA) Investors of Class Action Deadline and Last Few Hours to Actively Participate

New York, New York--(Newsfile Corp. - April 29, 2022) - Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.The lawsuit on behalf of Cabaletta investors has been commenced in the the United States District Court for the Eastern District of Pennsylvania. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable...

CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

News for Cabaletta Bio Stock (CABA)